AEGIS II

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

Objective

The primary objective of this study is to evaluate the efficacy of CSL112 on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects with ACS (diagnosed with STEMI or NSTEMI).

Eligibility

  • Evidence of myocardial necrosis, consistent with type I (spontaneous) MI
  • No suspicion of acute kidney injury
  • Evidence of multivessel coronary artery disease and at least 1 of the following established risk factors: age ≥ 65 years, prior history of MI, diabetes mellitus, or peripheral artery disease

NCT ID

NCT03473223